⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NNVC News
NanoViricides Inc.
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
accessnewswire.com
NNVC
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
accessnewswire.com
NNVC
Human Immunodeficiency Virus (HIV/AIDS
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
accessnewswire.com
NNVC
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
accessnewswire.com
NNVC
NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
accessnewswire.com
NNVC
NanoViricides, Inc. Has Filed its Annual Report
accessnewswire.com
NNVC
RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
accessnewswire.com
NNVC
NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
accessnewswire.com
NNVC